These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8643188)

  • 1. Visual loss complicating OKT3 monoclonal antibody therapy in a renal transplant recipient.
    Jin DC; Kim SY; Lee JM; Koo WS; Choi EJ; Yoon YS; Bang BK
    Nephrol Dial Transplant; 1995 Nov; 10(11):2144-6. PubMed ID: 8643188
    [No Abstract]   [Full Text] [Related]  

  • 2. [Aseptic meningitis due to OKT3].
    Uribe Roca MC; Zurru MC; Gatto EM; Maggiora EC; Agost Carreño C; Luciano M
    Neurologia; 1998 Feb; 13(2):98-9. PubMed ID: 9578680
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 4. Case 6: benefits and risks of OKT3 treatment in renal transplantation.
    First MR
    Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824
    [No Abstract]   [Full Text] [Related]  

  • 5. Uveitis associated with OKT3 therapy for renal transplant rejection.
    Gariano RF; Weitzman ML
    Br J Ophthalmol; 2001 Apr; 85(4):500-1. PubMed ID: 11302132
    [No Abstract]   [Full Text] [Related]  

  • 6. OKT3 monoclonal antibody therapy and visual loss.
    Horina JH; Horn S; Holzer H; Langmann G
    Nephrol Dial Transplant; 1996 Jul; 11(7):1497-8. PubMed ID: 8815436
    [No Abstract]   [Full Text] [Related]  

  • 7. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3].
    Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M
    Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
    Piatosa B; Grenda R; Prokurat S
    Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
    [No Abstract]   [Full Text] [Related]  

  • 10. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
    Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
    Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
    [No Abstract]   [Full Text] [Related]  

  • 12. OKT3 in renal allografts: survival and complications.
    D'Souza RJ; Kwan JT; Chang R; Bending MR
    Clin Nephrol; 1999 Apr; 51(4):257-8. PubMed ID: 10230561
    [No Abstract]   [Full Text] [Related]  

  • 13. [Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3].
    Müller T; Keuchel M; Schindler S; Steinmetz A; Feiber H; Lange H
    Helv Chir Acta; 1991 Sep; 58(3):271-5. PubMed ID: 1769844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
    Vasquez EM; Fabrega AJ; Pollak R
    Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
    [No Abstract]   [Full Text] [Related]  

  • 15. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of OKT3 nephrotoxicity after kidney transplantation.
    Abramowicz D; De Pauw L; Le Moine A; Sermon F; Surquin M; Doutrelepont JM; Ickx B; Depierreux M; Vanherweghem JL; Kinnaert P; Goldman M; Vereerstraeten P
    Kidney Int Suppl; 1996 Jan; 53():S39-43. PubMed ID: 8770989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 18. [Muromonab CD3].
    Akioka Y; Hattori M; Ito K
    Nihon Rinsho; 2005 May; 63 Suppl 5():747-50. PubMed ID: 15954439
    [No Abstract]   [Full Text] [Related]  

  • 19. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.
    Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term results of OKT3-treated renal transplant recipients.
    Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
    Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.